
Novaremed
Founded Year
2018Stage
Line of Credit | AliveTotal Raised
$65.83MLast Raised
$50M | 3 yrs agoNovaremed Patents
Novaremed has filed 5 patents.
The 3 most popular patent topics include:
- Amines
- Benzamides
- Enantiopure drugs

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
5/30/2014 | 7/5/2016 | Stereochemistry, Amines, Benzamides, Piperidines, Enantiopure drugs | Grant |
Application Date | 5/30/2014 |
---|---|
Grant Date | 7/5/2016 |
Title | |
Related Topics | Stereochemistry, Amines, Benzamides, Piperidines, Enantiopure drugs |
Status | Grant |
Latest Novaremed News
Jul 26, 2022
July 26, 2022 Neurofront Therapeutics Ltd. has picked up an option to acquire exclusive Asia rights to a phase II non-opioid drug from Novaremed AG. Under terms of the deal, Novaremed is eligible to receive more than $130 million in option and exercise fees as well as development, regulatory and sales milestone payments plus royalties on net sales. Shanghai, China-based Neurofront obtained rights to develop and commercialize the candidate in mainland China, Hong Kong, Macau, Taiwan and Singapore.
Novaremed Frequently Asked Questions (FAQ)
When was Novaremed founded?
Novaremed was founded in 2018.
Where is Novaremed's headquarters?
Novaremed's headquarters is located at Teichgaesslein 9, Basel.
What is Novaremed's latest funding round?
Novaremed's latest funding round is Line of Credit.
How much did Novaremed raise?
Novaremed raised a total of $65.83M.
Who are the investors of Novaremed?
Investors of Novaremed include Global Emerging Markets.